Authors : Priti Dalui; Joydeep Das; Banani Bindhani

Volume/Issue : Volume 11 - 2026, Issue 3 - March

Google Scholar : https://tinyurl.com/4v4s9e4p

Scribd : https://tinyurl.com/4hw3nb8j

DOI : https://doi.org/10.38124/ijisrt/26mar498

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Tripple negative breast cancer isthe most aggressive kinds of breast cancer having ER negative, PR negative & HER2 negative leading to limited treatment option. Recentstudiesshowed over expression of G protein – coupled estrogen Receptor in breast cancer cells. GPER is a membrane bound receptor mediate non-genomic signalling gathered attention for its complex role. GPER exhibit tumour promoting Properties through GFR – transactivation, PI3K/AKT, MAPK, CAMP, NFKB pathways leading to cancer. Development, proliferation, metastasis and epithelial mesenchymal transition (EMT). Likewise, GPER also having tumour suppressive role leading to caspase mediated apoptosis or cell cycle arrest in G2/M phase. GPER also inhibit proliferation, suppress EMT & reduce migratory potential suggesting a protective role against metastasis. Certain selective drugs of breast cancer like tamoxifen show resistance in GPER activated TNBC cells which cause GPER to be a potential target against breast cancer. This review explores along with mote dual role of GPER in TNBC, along with molecular mechanism & clinical approach of targeting GPER for therapeutic strategy challenging breast cancer subtypes.

Keywords : Tripple Negative Breast Cancer (TNBC), G-Protein Coupled Estrogen Receptor (GPER), PI3K/AKT, MAPK, CAMP, NFKB, Epithelial Mesenchymal Transition (EMT).

References :

1. Stabilization of MORC2 by estrogen and antiestrogens through GPER1 PRKACA- CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cellsJacquot, Y., Kampa, M., & Lindsey, S. H. (2021). Editorial: GPER: Control and Functions. Frontiers in endocrinology, 12, 794344. https://doi.org/10.3389/fendo.2021.794344
2. Fuentes, N., & Silveyra, P. (2019). Estrogen receptor signaling mechanisms. Advances in protein chemistry and structural biology, 116, 135–170. https://doi.org/10.1016/bs.apcsb.2019.01.001
3. Vrtačnik, P., Ostanek, B., Mencej-Bedrač, S., & Marc, J. (2014). The many faces of estrogen signaling. Biochemia medica, 24(3), 329–342. https://doi.org/10.11613/BM.2014.035
4. Samavat, H., & Kurzer, M. S. (2015). Estrogen metabolism and breast cancer. Cancer letters, 356(2 Pt A), 231–243. https://doi.org/10.1016/j.canlet.2014.04.018
5. Chen, P., Li, B., & Ou-Yang, L. (2022). Role of estrogen receptors in health and disease. Frontiers in endocrinology, 13, 839005. https://doi.org/10.3389/fendo.2022.839005
6. Treeck, O., Schüler-Toprak, S., & Ortmann, O. (2020). Estrogen Actions in Triple- Negative Breast Cancer. Cells, 9(11), 2358. https://doi.org/10.3390/cells9112358
7. Molina Calistro, L., Arancibia, Y., Olivera, M. A., Domke, S., & Torres, R. F. (2025). Interaction of GPER-1 with the endocrine signaling axis in breast cancer. Frontiers in endocrinology, 16, 1494411. https://doi.org/10.3389/fendo.2025.1494411
8. Hsu, L. H., Chu, N. M., Lin, Y. F., & Kao, S. H. (2019). G-Protein Coupled Estrogen Receptor in Breast Cancer. International journal of molecular sciences, 20(2), 306. https://doi.org/10.3390/ijms20020306
9. Zhang, D., Chen, H., Wang, J., Ji, J., Imam, M., Zhang, Z., & Yan, S. (2024). Current progress and prospects for G protein-coupled estrogen receptor in triple-negative breast cancer. Frontiers in cell and developmental biology, 12, 1338448. https://doi.org/10.3389/fcell.2024.1338448
10. Prossnitz, E. R., & Barton, M. (2023). The G protein-coupled oestrogen receptor GPER in health and disease: an update. Nature reviews. Endocrinology, 19(7), 407–424. https://doi.org/10.1038/s41574-023-00822-7
11. Zimmerman, M. A., Budish, R. A., Kashyap, S., & Lindsey, S. H. (2016). GPER-novel membrane oestrogen receptor. Clinical science (London, England : 1979), 130(12), 1005–1016. https://doi.org/10.1042/CS20160114
12. Carmeci, C., Thompson, D. A., Ring, H. Z., Francke, U., & Weigel, R. J. (1997). Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics, 45(3), 607–617. https://doi.org/10.1006/geno.1997.4972
13. Torres-López, L., Olivas-Aguirre, M., & Dobrovinskaya, O. (2024). The G Protein- Coupled Estrogen Receptor G
14. PER in the Development and Progression of Cancer. Receptors, 3(2), 220-254. https://doi.org/10.3390/receptors3020012
15. Tirado-Garibay, A. C., Falcón-Ruiz, E. A., Ochoa-Zarzosa, A., & López-Meza, J. E. (2023). GPER: An Estrogen Receptor Key in Metastasis and Tumoral Microenvironments. International journal of molecular sciences, 24(19), 14993. https://doi.org/10.3390/ijms241914993
16. Marjon, N. A., Hu, C., Hathaway, H. J., & Prossnitz, E. R. (2014). G protein-coupled estrogen receptor regulates mammary tumorigenesis and metastasis. Molecular cancer research : MCR, 12(11), 1644–1654. https://doi.org/10.1158/1541-7786.MCR-14- 0128-T
17. Mariana, S. M., Brenda, R. P., Heriberto, P. G., Cristina, L., David, B., & Guadalupe, Á. L. (2025). GPER1 activation by estrogenic compounds in the inflammatory profile of breast cancer cells. The Journal of steroid biochemistry and molecular biology, 245, 106639. https://doi.org/10.1016/j.jsbmb.2024.106639
18. Vivacqua A. (2020). GPER1 and microRNA: Two Players in Breast Cancer Progression. International journal of molecular sciences, 22(1), 98. https://doi.org/10.3390/ijms22010098
19. Yang, H., Wang, C., Liao, H., & Wang, Q. (2021). Activation of GPER by E2 promotes proliferation, invasion and migration of breast cancer cells by regulating the miR- 124/CD151 pathway. Oncology letters, 21(6), 432. https://doi.org/10.3892/ol.2021.12693
20. Vivacqua, A., Sebastiani, A., Miglietta, A. M., Rigiracciolo, D. C., Cirillo, F., Galli, G. R., Talia, M., Santolla, M. F., Lappano, R., Giordano, F., Panno, M. L., & Maggiolini, M. (2018). miR-338-3p Is Regulated by Estrogens through GPER in Breast Cancer Cells and Cancer-Associated Fibroblasts (CAFs). Cells, 7(11), 203. https://doi.org/10.3390/cells7110203
21. Yang, K., & Yao, Y. (2019). Mechanism of GPER promoting proliferation, migration and invasion of triple-negative breast cancer cells through CAF. American journal of translational research, 11(9), 5858–5868.
22. Cirillo, F., Lappano, R., Bruno, L., Rizzuti, B., Grande, F., Guzzi, R., Briguori, S., Miglietta, A. M., Nakajima, M., Di Martino, M. T., & Maggiolini, M. (2019). AHR and GPER mediate the stimulatory effects induced by 3-methylcholanthrene in breast cancer cells and cancer-associated fibroblasts (CAFs). Journal of experimental & clinical cancer research : CR, 38(1), 335. https://doi.org/10.1186/s13046-019-1337-2
23. He, C., Peng, M., Zeng, X., Dong, H., Sun, Z., Xu, J., Liu, M., Liu, L., Huang, Y., Peng, Z., Qiu, Y. A., Jiang, C., Xu, B., & Yu, T. (2024). Microenvironmental G protein- coupled estrogen receptor-mediated glutamine metabolic coupling between cancer- associated fibroblasts and triple-negative breast cancer cells governs tumour progression. Clinical and translational medicine, 14(12), e70131. https://doi.org/10.1002/ctm2.70131
24. Vivacqua, A., De Marco, P., Santolla, M. F., Cirillo, F., Pellegrino, M., Panno, M. L., Abonante, S., & Maggiolini, M. (2015). Estrogenic gper signaling regulates mir144 expression in cancer cells and cancer-associated fibroblasts (cafs). Oncotarget, 6(18), 16573–16587. https://doi.org/10.18632/oncotarget.4117
25. Chong Shuai, Xinmei Yang, Hongming Pan, Weidong Han, Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8+ T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer, Frontiers in Oncology, 10, (2020).https://doi.org/10.3389/fonc.2020.582863
26. Segovia-Mendoza, M., Mirzaei, E., Prado-Garcia, H., Miranda, L. D., Figueroa, A., & Lemini, C. (2022). The Interplay of GPER1 with 17β-Aminoestrogens in the Regulation of the Proliferation of Cervical and Breast Cancer Cells: A Pharmacological Approach. International journal of environmental research and public health, 19(19), 12361. https://doi.org/10.3390/ijerph191912361
27. Liarte, S., Alonso-Romero, J. L., & Nicolás, F. J. (2018). SIRT1 and Estrogen Signaling Cooperation for Breast Cancer Onset and Progression. Frontiers in endocrinology, 9, 552. https://doi.org/10.3389/fendo.2018.00552
28. Molina, L., Bustamante, F., Ortloff, A., Ramos, I., Ehrenfeld, P., & Figueroa, C. D. (2020). Continuous Exposure of Breast Cancer Cells to Tamoxifen Upregulates GPER-1 and Increases Cell Proliferation. Frontiers in endocrinology, 11, 563165. https://doi.org/10.3389/fendo.2020.563165
29. Maharjan, C. K., Mo, J., Wang, L., Kim, M. C., Wang, S., Borcherding, N., Vikas, P., & Zhang, W. (2021). Natural and Synthetic Estrogens in Chronic Inflammation and Breast Cancer. Cancers, 14(1), 206. https://doi.org/10.3390/cancers14010206
30. Janik, M. E., Bełkot, K., & Przybyło, M. (2014). Is oestrogen an important player in melanoma progression?. Contemporary oncology (Poznan, Poland), 18(5), 302–306. https://doi.org/10.5114/wo.2014.43938
31. Honma, N., Matsuda, Y., & Mikami, T. (2021). Carcinogenesis of Triple-Negative Breast Cancer and Sex Steroid Hormones. Cancers, 13(11), 2588. https://doi.org/10.3390/cancers13112588
32. Hoang, L. N., & Lee, S. J. (2023). Casein kinase 1 controls the shuttling of epidermal growth factor receptor and estrogen receptor in endometrial carcinoma induced by breast cancer hormonal therapy: Relevance of GPER1/Src. Cellular signalling, 108, 110733. https://doi.org/10.1016/j.cellsig.2023.110733
33. Vella, V., De Francesco, E. M., Lappano, R., Muoio, M. G., Manzella, L., Maggiolini, M., & Belfiore, A. (2020). Microenvironmental Determinants of Breast Cancer Metastasis: Focus on the Crucial Interplay Between Estrogen and Insulin/Insulin-Like Growth Factor Signaling. Frontiers in cell and developmental biology, 8, 608412. https://doi.org/10.3389/fcell.2020.608412
34. Fan, D. X., Yang, X. H., Li, Y. N., & Guo, L. (2018). 17β-Estradiol on the Expression of G-Protein Coupled Estrogen Receptor (GPER/GPR30) Mitophagy, and the PI3K/Akt Signaling Pathway in ATDC5 Chondrocytes In Vitro. Medical science monitor : international medical journal of experimental and clinical research, 24, 1936–1947. https://doi.org/10.12659/msm.909365
35. Chen, Z. J., Wei, W., Jiang, G. M., Liu, H., Wei, W. D., Yang, X., Wu, Y. M., Liu, H., Wong, C. K., Du, J., & Wang, H. S. (2016). Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-κB signals. Molecular oncology, 10(6), 775–788. https://doi.org/10.1016/j.molonc.2016.01.002
36. Shi, D., Li, H., Zhang, Z., He, Y., Chen, M., Sun, L., & Zhao, P. (2022). Cryptotanshinone inhibits proliferation and induces apoptosis of breast cancer MCF-7 cells via GPER mediated PI3K/AKT signaling pathway. PloS one, 17(1), e0262389. https://doi.org/10.1371/journal.pone.0262389
37. Notas, G., Panagiotopoulos, A., Vamvoukaki, R., Kalyvianaki, K., Kiagiadaki, F., Deli, A., Kampa, M., & Castanas, E. (2021). ERα36-GPER1 Collaboration Inhibits TLR4/NFκB-Induced Pro-Inflammatory Activity in Breast Cancer Cells. International journal of molecular sciences, 22(14), 7603. https://doi.org/10.3390/ijms22147603
38. Pepermans, R. A., & Prossnitz, E. R. (2019). ERα-targeted endocrine therapy, resistance and the role of GPER. Steroids, 152, 108493. https://doi.org/10.1016/j.steroids.2019.108493
39. Ignatov, T., Weißenborn, C., Poehlmann, A., Lemke, A., Semczuk, A., Roessner, A., Costa, S. D., Kalinski, T., & Ignatov, A. (2013). GPER-1 expression decreases during breast cancer tumorigenesis. Cancer investigation, 31(5), 309–315. https://doi.org/10.3109/07357907.2013.789901
40. Vaziri-Gohar, A., & Houston, K. D. (2016). GPER1-mediated IGFBP-1 induction modulates IGF-1-dependent signaling in tamoxifen-treated breast cancer cells. Molecular and cellular endocrinology, 422, 160–171. https://doi.org/10.1016/j.mce.2015.11.033
41. Shi, D., Zhao, P., Cui, L., Li, H., Sun, L., Niu, J., & Chen, M. (2020). Inhibition of PI3K/AKT molecular pathway mediated by membrane estrogen receptor GPER accounts for cryptotanshinone induced antiproliferative effect on breast cancer SKBR- 3 cells. BMC pharmacology & toxicology, 21(1), 32. https://doi.org/10.1186/s40360-020-00410-9
42. Wang, C., Li, J., Ye, S., Zhang, Y., Li, P., Wang, L., & Wang, T. H. (2018). Oestrogen Inhibits VEGF Expression And Angiogenesis In Triple-Negative Breast Cancer By Activating GPER-1. Journal of Cancer, 9(20), 3802–3811. https://doi.org/10.7150/jca.29233
43. Tao, S., He, H., & Chen, Q. (2015). Estradiol induces HOTAIR levels via GPER- mediated miR-148a inhibition in breast cancer. Journal of translational medicine, 13, 131. https://doi.org/10.1186/s12967-015-0489-x
44. Yang, F., Xie, H. Y., Yang, L. F., Zhang, L., Zhang, F. L., Liu, H. Y., Li, D. Q., & Shao, Z. M. (2020). Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells. Autophagy, 16(6), 1061–1076. https://doi.org/10.1080/15548627.2019.1659609
45. Huang, R., Li, J., Pan, F., Zhang, B., & Yao, Y. (2020). The activation of GPER inhibits cells proliferation, invasion and EMT of triple-negative breast cancer via CD151/miR- 199a-3p bio-axis. American journal of translational research, 12(1), 32–44.
46. Talia, M., Cirillo, F., Scordamaglia, D., Di Dio, M., Zicarelli, A., De Rosis, S., Miglietta, A. M., Capalbo, C., De Francesco, E. M., Belfiore, A., Grande, F., Rizzuti, B., Occhiuzzi, M. A., Fortino, G., Guzzo, A., Greco, G., Maggiolini, M., & Lappano, R. (2024). The G Protein Estrogen Receptor (GPER) is involved in the resistance to the CDK4/6 inhibitor palbociclib in breast cancer. Journal of experimental & clinical cancer research : CR, 43(1), 171. https://doi.org/10.1186/s13046-024-03096-7
47. Emons, G., Mustea, A., & Tempfer, C. (2020). Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers, 12(9), 2535. https://doi.org/10.3390/cancers12092535
48. Rondón-Lagos, M., Villegas, V. E., Rangel, N., Sánchez, M. C., & Zaphiropoulos, P. G. (2016). Tamoxifen Resistance: Emerging Molecular Targets. International journal of molecular sciences, 17(8), 1357. https://doi.org/10.3390/ijms17081357
49. Hall, K. A., & Filardo, E. J. (2023). The G Protein-Coupled Estrogen Receptor (GPER): A Critical Therapeutic Target for Cancer. Cells, 12(20), 2460. https://doi.org/10.3390/cells12202460
50. Rouhimoghadam, M., Lu, A. S., Salem, A. K., & Filardo, E. J. (2020). Therapeutic Perspectives on the Modulation of G-Protein Coupled Estrogen Receptor, GPER, Function.   Frontiers in endocrinology, 11, 591217. https://doi.org/10.3389/fendo.2020.591217
51. Shen, J., He, Y., Li, S., & Chen, H. (2024). Crosstalk of methylation and tamoxifen in breast cancer (Review). Molecular medicine reports, 30(4), 180. https://doi.org/10.3892/mmr.2024.13304
52. Weißenborn, C., Ignatov, T., Ochel, HJ. et al. GPER functions as a tumor suppressor in triple-negative breast cancer cells. J Cancer Res Clin Oncol 140, 713–723 (2014). https://doi.org/10.1007/s00432-014-1620-8
53. He, Y., Yang, K., Liu, J., Shi, D., Zhang, Z., Yang, J., Chen, M., & Zhao, P. (2023). Tanshinone IIA Inhibits Triple-Negative Breast Cancer Cells MDA-MB-231 via G Protein-Coupled Estrogen Receptor- (GPER-) Dependent Signaling Pathway. Disease markers, 2023, 8371623. https://doi.org/10.1155/2023/8371623
54. Kampa, M., Lappano, R., Grande, F., Rizzuti, B., Maggiolini, M., Castanas, E., & Jacquot, Y. (2023). Promising Perspectives of the Antiproliferative GPER Inverse Agonist ERα17p in Breast Cancer. Cells, 12(4), 653. https://doi.org/10.3390/cells12040653
55. Kim, K. M., & Jung, J. (2020). Upregulation of G Protein-Coupled Estrogen Receptor by Chrysin-Nanoparticles Inhibits Tumor Proliferation and Metastasis in Triple Negative Breast Cancer Xenograft Model. Frontiers in endocrinology, 11, 560605. https://doi.org/10.3389/fendo.2020.560605
56. Cirillo, F., Spinelli, A., Talia, M. et al. Estetrol/GPER/SERPINB2 transduction signaling inhibits the motility of triple-negative breast cancer cells. J Transl Med 22, 450 (2024). https://doi.org/10.1186/s12967-024-05269-6
57. Ignatov, T., Modl, S., Thulig, M. et al. GPER-1 acts as a tumor suppressor in ovarian cancer. J Ovarian Res 6, 51 (2013). https://doi.org/10.1186/1757-2215-6-51
58. Gallo Cantafio, M. E., Torcasio, R., Scionti, F., Mesuraca, M., Ronchetti, D., Pistoni, M., Bellizzi, D., Passarino, G., Morelli, E., Neri, A., Viglietto, G., & Amodio, N. (2023). GPER1 Activation Exerts Anti-Tumor Activity in Multiple Myeloma. Cells, 12(18), 2226. https://doi.org/10.3390/cells12182226